Literature DB >> 20576017

Enhanced classification of Chagas serologic results and epidemiologic characteristics of seropositive donors at three large blood centers in Brazil.

Ester C Sabino1, Nanci A Salles, Moussa Sarr, Angela M Barreto, Marcio Oikawa, Cláudia D Oliveira, Silvana C Leao, Anna B Carneiro-Proietti, Brian Custer, Michael P Busch.   

Abstract

BACKGROUND: A major problem in Chagas disease donor screening is the high frequency of samples with inconclusive results. The objective of this study was to describe patterns of serologic results among donors to the three Brazilian REDS-II blood centers and correlate with epidemiologic characteristics. STUDY DESIGN AND METHODS: The centers screened donor samples with one Trypanosoma cruzi lysate enzyme immunoassay (EIA). EIA-reactive samples were tested with a second lysate EIA, a recombinant-antigen based EIA, and an immunfluorescence assay. Based on the serologic results, samples were classified as confirmed positive (CP), probable positive (PP), possible other parasitic infection (POPI), and false positive (FP).
RESULTS: In 2007 to 2008, a total of 877 of 615,433 donations were discarded due to Chagas assay reactivity. The prevalences (95% confidence intervals [CIs]) among first-time donors for CP, PP, POPI, and FP patterns were 114 (99-129), 26 (19-34), 10 (5-14), and 96 (82-110) per 100,000 donations, respectively. CP and PP had similar patterns of prevalence when analyzed by age, sex, education, and location, suggesting that PP cases represent true T. cruzi infections; in contrast the demographics of donors with POPI were distinct and likely unrelated to Chagas disease. No CP cases were detected among 218,514 repeat donors followed for a total of 718,187 person-years.
CONCLUSION: We have proposed a classification algorithm that may have practical importance for donor counseling and epidemiologic analyses of T. cruzi-seroreactive donors. The absence of incident T. cruzi infections is reassuring with respect to risk of window phase infections within Brazil and travel-related infections in nonendemic countries such as the United States.
© 2010 American Association of Blood Banks.

Entities:  

Mesh:

Year:  2010        PMID: 20576017      PMCID: PMC2997114          DOI: 10.1111/j.1537-2995.2010.02756.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  20 in total

1.  Serologic testing for Trypanosoma cruzi: comparison of radioimmunoprecipitation assay with commercially available indirect immunofluorescence assay, indirect hemagglutination assay, and enzyme-linked immunosorbent assay kits.

Authors:  D A Leiby; S Wendel; D T Takaoka; R M Fachini; L C Oliveira; M A Tibbals
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

2.  Risk of exposure to Chagas' disease among seroreactive Brazilian blood donors.

Authors:  N A Salles; E C Sabino; M G Cliquet; J Eluf-Neto; A Mayer; C Almeida-Neto; M C Mendonça; P Dorliach-Llacer; D F Chamone; A Saéz-Alquézar
Journal:  Transfusion       Date:  1996 Nov-Dec       Impact factor: 3.157

3.  Human infection by Trypanosoma rangeli in the Brazilian Amazon.

Authors:  J R Coura; O Fernandes; M Arboleda; T V Barrett; N Carrara; W Degrave; D A Campbell
Journal:  Trans R Soc Trop Med Hyg       Date:  1996 May-Jun       Impact factor: 2.184

4.  Evaluation of recombinant antigens for serodiagnosis of Chagas' disease in South and Central America.

Authors:  E S Umezawa; S F Bastos; M E Camargo; L M Yamauchi; M R Santos; A Gonzalez; B Zingales; M J Levin; O Sousa; R Rangel-Aldao; J F da Silveira
Journal:  J Clin Microbiol       Date:  1999-05       Impact factor: 5.948

5.  Chagas' disease diagnosis: evaluation of several tests in blood bank screening.

Authors:  M R Carvalho; M A Krieger; E Almeida; W Oelemann; M A Shikanai-Yassuda; A W Ferreira; J B Pereira; A Sáez-Alquézar; P E Dorlhiac-Llacer; D F Chamone
Journal:  Transfusion       Date:  1993-10       Impact factor: 3.157

6.  Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial.

Authors:  Rodolfo Viotti; Carlos Vigliano; Bruno Lococo; Graciela Bertocchi; Marcos Petti; María Gabriela Alvarez; Miriam Postan; Alejandro Armenti
Journal:  Ann Intern Med       Date:  2006-05-16       Impact factor: 25.391

7.  Evaluation of a prototype Trypanosoma cruzi antibody assay with recombinant antigens on a fully automated chemiluminescence analyzer for blood donor screening.

Authors:  Chi-Deu Chang; Kevin Y Cheng; Lily X Jiang; Vince A Salbilla; Alla S Haller; Alex W Yem; Jane D Bryant; Louis V Kirchhoff; David A Leiby; Gerald Schochetman; Dinesh O Shah
Journal:  Transfusion       Date:  2006-10       Impact factor: 3.157

8.  Demographic profile of blood donors at three major Brazilian blood centers: results from the International REDS-II study, 2007 to 2008.

Authors:  Anna Bárbara Carneiro-Proietti; Ester C Sabino; Divaldo Sampaio; Fernando A Proietti; Thelma T Gonçalez; Cláudia D L Oliveira; João E Ferreira; Jing Liu; Brian Custer; George B Schreiber; Edward L Murphy; Michael P Busch
Journal:  Transfusion       Date:  2009-12-10       Impact factor: 3.157

9.  Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection.

Authors:  A L de Andrade; F Zicker; R M de Oliveira; S Almeida Silva; A Luquetti; L R Travassos; I C Almeida; S S de Andrade; J G de Andrade; C M Martelli
Journal:  Lancet       Date:  1996-11-23       Impact factor: 79.321

10.  Evaluation of serological tests to identify Trypanosoma cruzi infection in humans and determine cross-reactivity with Trypanosoma rangeli and Leishmania spp.

Authors:  Zuleima C Caballero; Octavio E Sousa; Waldelania P Marques; Amadeo Saez-Alquezar; Eufrosina S Umezawa
Journal:  Clin Vaccine Immunol       Date:  2007-05-23
View more
  14 in total

1.  The National Heart, Lung, and Blood Institute retrovirus epidemiology donor studies (Retrovirus Epidemiology Donor Study and Retrovirus Epidemiology Donor Study-II): twenty years of research to advance blood product safety and availability.

Authors:  Steven Kleinman; Melissa R King; Michael P Busch; Edward L Murphy; Simone A Glynn
Journal:  Transfus Med Rev       Date:  2012-05-24

Review 2.  Trypanosoma cruzi and Chagas' Disease in the United States.

Authors:  Caryn Bern; Sonia Kjos; Michael J Yabsley; Susan P Montgomery
Journal:  Clin Microbiol Rev       Date:  2011-10       Impact factor: 26.132

3.  Performance of six diagnostic tests to screen for Chagas disease in blood banks andprevalence of Trypanosoma cruzi infection among donors with inconclusive serologyscreening based on the analysis of epidemiological variables.

Authors:  Gilberto de Araujo Pereira; Francisco Louzada-Neto; Valdirene de Fátima Barbosa; Márcia Maria Ferreira-Silva; Helio de Moraes-Souza
Journal:  Rev Bras Hematol Hemoter       Date:  2012

4.  Anti-Trypanosoma cruzi inconclusive results in blood donor screening.

Authors:  Márcia Mitiko Otani
Journal:  Rev Bras Hematol Hemoter       Date:  2012

5.  Antibody levels correlate with detection of Trypanosoma cruzi DNA by sensitive polymerase chain reaction assays in seropositive blood donors and possible resolution of infection over time.

Authors:  Ester C Sabino; Tzong-Hae Lee; Lani Montalvo; Megan L Nguyen; David A Leiby; Danielle M Carrick; Marcia M Otani; Elizabeth Vinelli; David Wright; Susan L Stramer; Michael Busch
Journal:  Transfusion       Date:  2012-09-25       Impact factor: 3.157

6.  Methodological Guidelines for Reducing the Complexity of Data Warehouse Development for Transactional Blood Bank Systems.

Authors:  Pedro L Takecian; Marcio K Oikawa; Kelly R Braghetto; Paulo Rocha; Fred Lucena; Katherine Kavounis; Karen S Schlumpf; Susan Acker; Anna B F Carneiro-Proietti; Ester C Sabino; Brian Custer; Michael P Busch; João E Ferreira
Journal:  Decis Support Syst       Date:  2013-06-01       Impact factor: 5.795

7.  Prevalence of Trypanosoma Cruzi Infection in Blood Donors.

Authors:  Alanna Carla da Costa; Eduardo Arrais Rocha; José Damião da Silva Filho; Arduina Sofia Ortet de Barros Vasconcelos Fidalgo; Francisca Mylena Melgaço Nunes; Carlos Eduardo Menezes Viana; Vânia Barreto Aguiar F Gomes; Maria de Fátima Oliveira
Journal:  Arq Bras Cardiol       Date:  2020-12       Impact factor: 2.000

8.  Contribution of the Retrovirus Epidemiology Donor Study (REDS) to research on blood transfusion safety in Brazil.

Authors:  Paula Loureiro; Cesar de Almeida-Neto; Anna Bárbara Carneiro Proietti; Ligia Capuani; Thelma Terezinha Gonçalez; Claudia Di Lorenzo de Oliveira; Silvana Carneiro Leão; Maria Inês Lopes; Divaldo Sampaio; Giuseppina Maria Patavino; João Eduardo Ferreira; Paula Fraiman Blatyta; Maria Esther Duarte Lopes; Alfredo Mendrone-Junior; Nanci Alves Salles; Melissa King; Edward Murphy; Michael Busch; Brian Custer; Ester Cerdeira Sabino
Journal:  Rev Bras Hematol Hemoter       Date:  2014-03

9.  FC-TRIPLEX Chagas/Leish IgG1: a multiplexed flow cytometry method for differential serological diagnosis of chagas disease and leishmaniasis.

Authors:  Andréa Teixeira-Carvalho; Fernanda Magalhães Freire Campos; Stefan Michael Geiger; Roberta Dias Rodrigues Rocha; Fernanda Fortes de Araújo; Danielle Marquete Vitelli-Avelar; Mariléia Chaves Andrade; Márcio Sobreira Silva Araújo; Elenice Moreira Lemos; Anna Bárbara de Freitas Carneiro Proietti; Ester Cerdeira Sabino; Rafaella Gaiotti Caldas; Carolina Renata Camargos Freitas; Ana Carolina Campi-Azevedo; Silvana Maria Elói-Santos; Olindo Assis Martins-Filho
Journal:  PLoS One       Date:  2015-04-15       Impact factor: 3.240

10.  Electrocardiographic abnormalities in Trypanosoma cruzi seropositive and seronegative former blood donors.

Authors:  Antonio L Ribeiro; Ester C Sabino; Milena S Marcolino; Vera M C Salemi; Barbara M Ianni; Fábio Fernandes; Luciano Nastari; André Antunes; Márcia Menezes; Cláudia Di Lorenzo Oliveira; Vandana Sachdev; Danielle M Carrick; Michael P Busch; Eduard L Murphy
Journal:  PLoS Negl Trop Dis       Date:  2013-02-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.